Skip to main content

Table 2 Relationship between JCV positivity and MRI and clinical outcomes

From: May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study

Endpoint

JCV-

JCV+

p-value

ARR on 24 months

0.10 ± 0.25

0.083 ± 0.24

0.82

New T2 lesions at 24 months

5.6 ± 9.1

9.5 ± 14.9

0.23

Disability progression, n (%)

3/73 (4.1)

6/68 (8.8)

0.31

  1. Results are reported as mean ± SD except where differently stated